Stocktoria
iBio, Inc. IBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-08-18
iBio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $400,000 | $225,000 | $0 | $1.9M | $2.4M |
| Gross profit | — | — | — | $2.2M | $909,000 |
| R&D expense | $8.3M | $5.2M | $10.3M | $9.8M | $10.0M |
| Operating income | -$18.6M | -$16.6M | -$29.3M | -$29.7M | -$31.1M |
| Interest expense | — | — | $83,000 | $1.4M | $2.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.4M | -$24.9M | -$65.0M | -$50.3M | -$23.2M |
| EPS (diluted) | $-1.75 | $-6.50 | $-106.19 | $-5.78 | $-3.00 |
| Operating cash flow | -$15.3M | -$18.6M | -$30.4M | -$37.5M | -$30.1M |
| Free cash flow | -$15.3M | -$18.8M | -$36.2M | -$44.8M | -$35.0M |
| Cash & equivalents | $8.6M | $14.2M | $4.3M | $22.7M | $77.4M |
| Inventory | — | $0 | $0 | $3.9M | $27,000 |
| Total assets | $23.2M | $28.7M | $41.2M | $99.4M | $147.0M |
| Total liabilities | $8.3M | $7.4M | $25.8M | $35.9M | $38.4M |
| Shareholders' equity | $14.9M | $21.3M | $15.4M | $63.5M | $108.6M |
Source: SEC EDGAR filings · CIK 0001420720 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.